(b)(4).Concomitant products: stent: 2.75x8 rx xience alpine; 3.5x18 rx xience alpine.The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of ventricular tachycardia is listed in the xience alpine everolimus eluting coronary stent system electronic instructions for use, (ifu) as a known patient effect of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.
|
It was reported that on (b)(6) 2016, a 2.5x12 rx xience alpine, a 2.75x8 rx xience alpine, and a 3.5x18 rx xience alpine drug-eluting stent were implanted for treatment of an unspecified vessel.On (b)(6) 2016, the patient was rehospitalized due to abnormal echocardiogram test results with ventricular tachycardia.Unspecified treatment was administered and the final patient outcome is reportedly unknown.No additional information was provided.
|